168 related articles for article (PubMed ID: 36514736)
1. Enhanced SHP-1 Expression in Podocyturia Is Associated with Kidney Dysfunction in Patients with Diabetes.
Lizotte F; Robillard S; Lavoie N; Rousseau M; Denhez B; Moreau J; Higgins S; Sabbagh R; Côté AM; Geraldes P
Kidney360; 2022 Oct; 3(10):1710-1719. PubMed ID: 36514736
[TBL] [Abstract][Full Text] [Related]
2. Deletion of protein tyrosine phosphatase SHP-1 restores SUMOylation of podocin and reverses the progression of diabetic kidney disease.
Lizotte F; Rousseau M; Denhez B; Lévesque D; Guay A; Liu H; Moreau J; Higgins S; Sabbagh R; Susztak K; Boisvert FM; Côté AM; Geraldes P
Kidney Int; 2023 Oct; 104(4):787-802. PubMed ID: 37507049
[TBL] [Abstract][Full Text] [Related]
3. Urinary podocyte stress marker as a prognostic indicator for diabetic kidney disease.
Zeng L; Ng JK; Fung WW; Chan GC; Chow KM; Szeto CC
BMC Nephrol; 2024 Jan; 25(1):32. PubMed ID: 38267859
[TBL] [Abstract][Full Text] [Related]
4. Increased SHP-1 protein expression by high glucose levels reduces nephrin phosphorylation in podocytes.
Denhez B; Lizotte F; Guimond MO; Jones N; Takano T; Geraldes P
J Biol Chem; 2015 Jan; 290(1):350-8. PubMed ID: 25404734
[TBL] [Abstract][Full Text] [Related]
5. Persistent Insulin Resistance in Podocytes Caused by Epigenetic Changes of SHP-1 in Diabetes.
Lizotte F; Denhez B; Guay A; Gévry N; Côté AM; Geraldes P
Diabetes; 2016 Dec; 65(12):3705-3717. PubMed ID: 27585521
[TBL] [Abstract][Full Text] [Related]
6. Saxagliptin attenuates glomerular podocyte injury by increasing the expression of renal nephrin and podocin in type 2 diabetic rats.
Hu Y; Ye S; Xing Y; Lv L; Hu W; Zhou W
Acta Diabetol; 2020 Mar; 57(3):279-286. PubMed ID: 31535208
[TBL] [Abstract][Full Text] [Related]
7. Podocyturia parallels proximal tubule dysfunction in type 2 diabetes mellitus patients independently of albuminuria and renal function decline: A cross-sectional study.
Petrica L; Vlad M; Vlad A; Gluhovschi G; Gadalean F; Dumitrascu V; Popescu R; Gluhovschi C; Matusz P; Velciov S; Bob F; Ursoniu S; Vlad D
J Diabetes Complications; 2017 Sep; 31(9):1444-1450. PubMed ID: 28161386
[TBL] [Abstract][Full Text] [Related]
8. Therapy with atorvastatin versus rosuvastatin reduces urinary podocytes, podocyte-associated molecules, and proximal tubule dysfunction biomarkers in patients with type 2 diabetes mellitus: a pilot study.
Vlad A; Vlad M; Petrica L; Ursoniu S; Gadalean F; Popescu R; Vlad D; Dumitrascu V; Gluhovschi G; Gluhovschi C; Velciov S; Bob F; Matusz P; Secara A; Simulescu A; Jianu DC
Ren Fail; 2017 Nov; 39(1):112-119. PubMed ID: 27841047
[TBL] [Abstract][Full Text] [Related]
9. MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease.
He M; Li Y; Wang L; Guo B; Mei W; Zhu B; Zhang J; Ding Y; Meng B; Zhang L; Xiang L; Dong J; Liu M; Xiang L; Xiang G
Diabetologia; 2020 Sep; 63(9):1916-1931. PubMed ID: 32588068
[TBL] [Abstract][Full Text] [Related]
10. Increased Urinary Excretion of Podocyte Markers in Normoalbuminuric Patients with Diabetes.
Lioudaki E; Stylianou KG; Petrakis I; Kokologiannakis G; Passam A; Mikhailidis DP; Daphnis EK; Ganotakis ES
Nephron; 2015; 131(1):34-42. PubMed ID: 26340089
[TBL] [Abstract][Full Text] [Related]
11. Dopamine 1 receptor activation protects mouse diabetic podocytes injury via regulating the PKA/NOX-5/p38 MAPK axis.
Shao X; Zhang X; Hu J; Gao T; Chen J; Xu C; Wei C
Exp Cell Res; 2020 Mar; 388(2):111849. PubMed ID: 31954110
[TBL] [Abstract][Full Text] [Related]
12. Serum amyloid A and inflammation in diabetic kidney disease and podocytes.
Anderberg RJ; Meek RL; Hudkins KL; Cooney SK; Alpers CE; Leboeuf RC; Tuttle KR
Lab Invest; 2015 Mar; 95(3):250-62. PubMed ID: 25531567
[TBL] [Abstract][Full Text] [Related]
13. Urinary podocyte-associated mRNA profile in Egyptian patients with diabetic nephropathy.
Fayed A; Rahman Tohamy IA; Kahla H; Elsayed NM; El Ansary M; Saadi G
Diabetes Metab Syndr; 2019; 13(5):2849-2854. PubMed ID: 31425946
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice.
Xiao T; Guan X; Nie L; Wang S; Sun L; He T; Huang Y; Zhang J; Yang K; Wang J; Zhao J
Mol Cell Biochem; 2014 Sep; 394(1-2):145-54. PubMed ID: 24850187
[TBL] [Abstract][Full Text] [Related]
15. Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.
Jha JC; Thallas-Bonke V; Banal C; Gray SP; Chow BS; Ramm G; Quaggin SE; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
Diabetologia; 2016 Feb; 59(2):379-89. PubMed ID: 26508318
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model.
Wang S; Li Y; Zhao J; Zhang J; Huang Y
Biol Blood Marrow Transplant; 2013 Apr; 19(4):538-46. PubMed ID: 23295166
[TBL] [Abstract][Full Text] [Related]
17. Intra-renal and urinary mRNA expression of podocyte-associated molecules for the estimation of glomerular podocyte loss.
Wang G; Lai FM; Lai KB; Chow KM; Kwan BC; Li KT; Szeto CC
Ren Fail; 2010 Jan; 32(3):372-9. PubMed ID: 20370455
[TBL] [Abstract][Full Text] [Related]
18. Urinary podocyte mRNAs precede microalbuminuria as a progression risk marker in human type 2 diabetic nephropathy.
Fukuda A; Minakawa A; Kikuchi M; Sato Y; Nagatomo M; Nakamura S; Mizoguchi T; Fukunaga N; Shibata H; Naik AS; Wiggins RC; Fujimoto S
Sci Rep; 2020 Oct; 10(1):18209. PubMed ID: 33097787
[TBL] [Abstract][Full Text] [Related]
19. [The effects and mechanism of Tripterygium wilfordii Hook F combination with irbesartan on urinary podocyte excretion in diabetic nephropathy patients].
Ma RX; Zhao N; Zhang W
Zhonghua Nei Ke Za Zhi; 2013 Jun; 52(6):469-73. PubMed ID: 24059992
[TBL] [Abstract][Full Text] [Related]
20. TangShenWeiNing Formula Prevents Diabetic Nephropathy by Protecting Podocytes Through the SIRT1/HIF-1α Pathway.
Chang J; Zheng J; Gao X; Dong H; Yu H; Huang M; Sun Z; Feng X
Front Endocrinol (Lausanne); 2022; 13():888611. PubMed ID: 35721758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
